|
|
|
| home > ict > Spring 2019 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
|
 |
| |
|
|
|
|
End Point
Deadly Anti-Vaxxers
ICT’s Editor, Dr Graham Hughes, discusses the worrying increase in anti-vaxxers across the US and UK, highlighting the dangers of misinformation and unsubstantiated facts.
|
|
|
|
|
Q&A: Clinical Trials for Glioblastoma
Impatient Patients and a New Approach to Disease Treatment
Drawing from her own experience of glioblastoma, Jessica Morris at OurBrainBank talks to about the history of her company and her aim to empower patients by giving them back control of their own disease management.
|
|
|
|
Successful Clinical Trial Execution and Oversight
Efficient and Effective Vendor Management
LUMIS International’sHeike Schön and Dr Fernando Martinez explain the urgency for effective vendor management relationships for small and midsize sponsors.
|
|
|
|
Evaluating for Market
Achieving Successful Clinical Evaluation Reports
To assess the growing complications in clinical evaluation reports, Dr Efstathios Vassiliadis at Maetrics explores the history of medical device regulations and how to keep on top of a shifting regulatory landscape.
|
|
|
|
Achieving Growth Potential in Clinical Research
The CRA Gap
Dietmar Eglhofer at VIARES evaluates the alarming shortage of experienced certified research analysts, which poses a threat to the clinical research industry and is detrimental to the growth potential of CROs.
|
|
|
|
|
|
Evaluating Clinical Trial Satisfaction Rates
Busting the Patient Engagement Myth
BBK Worldwide’s Aaron Fleishman breaks down and challenges the commonly held beliefs about patient engagement and presents the opportunities ahead for clinical trial sponsors.
|
|
|
|
Patient Perceptions
Interpreting Patient Reported Outcomes: A Holistic Approach
Health Outcomes Insights’ Dr Keith Meadows presents a new approach to interpreting data from patient reported outcomes and advises on how to compensate for imperfect data.
|
|
|
|
Patient Engagement Technology in Clinical Trials
Enhancing the Patient Experience
New technological advances should be utilised by CROs and study sponsors to improve patient satisfaction and engagement, as discussed by James Munz and Chris Watson at ERT.
|
|
|
|
Patient Participation in Clinical Trials
Receptivity, Recruitment, and Retention
To alleviate the inherent problems with patient engagement and recruitment, Christian Burns, Joan Chambers, and Melissa Daley at ClinX push for new ways to drive ‘the three Rs’: receptivity, recruitment, and retention.
|
|
|
|
Implementing the Patient’s Voice in Clinical Trials
The Mosaic of Patient Engagement
Patient perspectives in clinical research are a significant talking point in the development of trial design technology. Worldwide Clinical Trials’ Barbara Zupancic and Dr Michael Murphy explore the value in implementing these technologies.
|
|
|
|
A Unified Approach to Patient Engagement
The Perverse Incentive
Matthew McCarty at ICON establishes a greater unified approach to patient engagement, retention, and compliance through patient-facing technologies.
|
|
|
|
|
Precision Medicine in Modern Day Oncology
The Patient Data Paradigm
Dr Aldo Poli at OPIS examines the use of precision medicine in treating cancer and the importance of approaching clinical research from the patient’s perspective.
|
|
|
|
Developing a Unified eClinical Platform
E Pluribus Unum: Out of Many, One
Oracle Health Sciences’ Craig Morgan addresses the numerous inefficiencies in organisational siloes and how consolidation technologies may be the answer.
|
|
|
|
Q&A: The Role of Technology in Clinical Trial Logistics
Utilising Technology on a Global Scale
Kyle Cunningham at Greenphire speaks with ICT about the use of new technologies in combatting the burdens of clinical trial research and logistics.
|
|
|
|
|
Making Clinical Trial Data Accessible to Patients
A Three-Pronged Strategy
Data transparency and disclosure are a vital talking point in the wider scope of clinical trial insurance. Thomas Wicks at Trialscope discusses options for more accessible data to patients on a local and global scale.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Turkish Cargo keeps growing steadily.
According to the international air cargo information provider WACD's September data, the global air cargo brand Turkish Cargo, which serves 126 countries of the world, grew significantly by achieving a tonnage increase of 8.8 percent in a sector wherein the global air cargo market shrank by -5.4 percent.
More info >> |
|
 |
White Papers |
 |
|
Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials
Perceptive Informatics
Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >> |
|
 |
Industry Events |
 |
ESMO Targeted Anticancer Therapies Congress 2020
2-4 March 2020, Paris, France
A unique and international mix of experts, researchers and decision
makers both from academia and industry across the globe, will convene
in Paris for a three-day Congress aiming at exchanging knowledge,
experience and research innovations in cancer.
TAT
2020 will focus, among others, on novel strategies in immuno-oncology,
personalised medicine and molecular tumour boards, preclinical studies
to identify effective combination therapies, use of microbiome, tumour
agnostic trials, ADC technology, oncolytics, multispecific biological
constructs and targeting cytokines.
Participating in TAT 2020 will offer you the possibility to take part in
interdisciplinary discussions inspiring new ideas and new
collaborations.
More info >> |
|
|
